KLI

Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report

Metadata Downloads
Abstract
Background: Adding ovarian function suppression (OFS) after chemotherapy improves survival in young women with moderate-and high-risk breast cancer. Assessment of ovarian function restoration after chemotherapy becomes critical for subsequent endocrine treatment and addressing fertility issues.

Patients and methods: In the adding OFS after chemotherapy trial, patients who resumed ovarian function up to 2 years after chemotherapy were randomised to receive either 5 years of tamoxifen or adding 2 years of OFS with tamoxifen. Ovarian function was evaluated from enrolment to randomisation, and patients who did not randomise because of amenorrhoea for 2 years received tamoxifen and were followed up for 5 years. Prospectively collected consecutive hormone levels (proportion of patients with premenopausal follicle-stimulating hormone [FSH] levels <30 mIU/mL and oestradiol [E2] levels >40 pg/mL) and history of menstruation were available for 1067 patients with breast cancer.

Results: Over 5 years of tamoxifen treatment, 69% of patients resumed menstruation and 98% and 74% of patients satisfied predefined ovarian function restoration as per serum FSH and E2 levels, respectively. Menstruation was restored in 91% of patients younger than 35 years at baseline, but in only 33% of 45-year-old patients over 5 years. Among these patients, 41% experienced menstruation restoration within 2 years after chemotherapy and 28% slowly restored menstruation after 2-5 years. Younger age (<35 years) at baseline, anthracycline without taxanes and <90 days of chemotherapy were predictors of menstruation restoration.

Conclusions: During 5 years of tamoxifen treatment after chemotherapy, two-thirds of the patients experienced menstruation restoration, especially patients younger than 35 years. Young age, Adriamycin without taxanes and short duration of chemotherapy appeared to have a positive effect on ovarian reserves in the long term.

Trial registration: ClinicalTrials.gov identifier: NCT00912548.

(c) 2021 Elsevier Ltd. All rights reserved.
Author(s)
강성수김선옥김성용김현아김희정남석진노우철박경화박병우안세현윤정한이민혁이수정이은숙임석아정용식정준조세헌한세환한원식허민희
Issued Date
2021
Type
Article
Keyword
ChemotherapyTamoxifenOvarian functionMenstruationFSHE2
DOI
10.1016/j.ejca.2021.03.017
URI
https://oak.ulsan.ac.kr/handle/2021.oak/8177
https://ulsan-primo.hosted.exlibrisgroup.com/primo-explore/fulldisplay?docid=TN_cdi_proquest_miscellaneous_2529922573&amp;context=PC&amp;vid=ULSAN&amp;lang=ko_KR&amp;search_scope=default_scope&amp;adaptor=primo_central_multiple_fe&amp;tab=default_tab&amp;query=any,contains,Five-year%20changes%20in%20ovarian%20function%20restoration%20in%20premenopausal%20patients%20with%20breast%20cancer%20taking%20tamoxifen%20after%20chemotherapy:%20An%20ASTRRA%20study%20report&amp;offset=0&amp;pcAvailability=true
Publisher
EUROPEAN JOURNAL OF CANCER
Location
네덜란드
Language
한국어
ISSN
0959-8049
Citation Volume
151
Citation Start Page
190
Citation End Page
200
Appears in Collections:
Medicine > Medicine
Authorize & License
  • Authorize공개
Files in This Item:
  • There are no files associated with this item.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.